Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Antipsychotic medication use in youth has been increasing since the mid-1990s.1 This development, most pronounced in the United States, has raised criticism about potential overuse because antipsychotics are prescribed mainly off-label, and their adverse effect burden for young people is worrisome. During the last decade, mostly short-term efficacy and tolerability data led to the regulatory approval of 6 different second-generation antipsychotics (SGAs) to treat youth with schizophrenia, bipolar mania, irritability associated with autism, and Tourette syndrome. However, youth are more susceptible to acute and long-term adverse effects of antipsychotic medications than are adults, especially weight gain and lipid and glucose abnormalities.2 Prolonged exposure to antipsychotic medications may also diminish brain volume and neuronal density. While volume reductions may actually be related to improved functional brain connectivity and cognitive performance compared with unmedicated patients experiencing their first episode of schizophrenia,3 effects during brain development and in patients without schizophrenia are unknown.
Correll CU, Blader JC. Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword. JAMA Psychiatry. 2015;72(9):859–860. doi:10.1001/jamapsychiatry.2015.0632
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: